03/12/2026
How can artificial intelligence support the discovery of new antibiotics?
In a recent Stat News article, Cesar de la Fuente-Nunez, Presidential Associate Professor in the Departments of Psychiatry, Microbiology, Bioengineering, Chemical and Biomolecular Engineering, and Chemistry, and Henry Skinner, CEO of the AMR Action Fund, explore both the opportunities and the structural considerations shaping antibiotic innovation.
AI tools can rapidly analyze large datasets and identify promising molecular candidates, opening new possibilities for drug discovery. At the same time, the authors note that economic and policy frameworks play a key role in determining whether new antibiotics advance from research to real-world use.
The piece offers an informed perspective on how science, industry, and policy intersect in the evolving landscape of antibiotic development.
Read the full article in Stat News: https://bit.ly/4rvQMLR
Penn Medicine / Penn Medicine- Clinical Research / Chemical and Biomolecular Engineering Department, Penn / Penn Engineering
Economic reality and the persistent absence of funding stand in the way of using AI for antibiotic breakthroughs.